Technology | April 17, 2015

Cerner and Qualcomm Collaborate on Home Health Monitoring Network

Qualcomm's 2net Platform will capture patient data from home, transmit it via Cerner's CareAware platform

Cerner, Qualcomm, home health monitoring, 2net, CareAware, EHR

April 17, 2015 — Cerner Corp. and Qualcomm Life Inc. announced an agreement to extend Cerner’s medical device connectivity capabilities beyond the hospital to the home. Cerner will leverage Qualcomm Life’s U.S. Food and Drug Administration (FDA)-listed 2net Platform and Hub to capture data from medical devices and sensors within a patient’s home, and transmit it to Cerner healthcare clients through Cerner’s CareAware device connectivity platform. Through this initiative, care providers can remotely monitor chronically ill patients in near-real time to enable proactive engagement to potentially reduce the risk of an acute care episode.

Qualcomm Life’s 2net Platform collects, stores and aggregates patient data from connected medical devices provided to the patient, such as weight scales, blood pressure monitors and pulse oximeters. These data values will transmit via CareAware to the Cerner Millennium electronic health record (EHR) and are viewable to the patient in HealtheLife, Cerner’s patient engagement solution. Extending CareAware to integrate devices within the home to the patient’s EHR will provide healthcare organizations a more comprehensive view in their efforts to focus on chronic condition management, reduce readmissions and improve patient health and satisfaction.

Qualcomm Life will join Cerner’s CareAware certification program, an initiative that creates alliances between Cerner and medical device manufacturers to better acquire data from devices to integrate with the EHR via CareAware device connectivity architecture.

Agnesian HealthCare is one of the first enterprise clients to implement the combined technologies to remotely monitor and manage at-risk patient populations. “It is increasingly important that providers are monitoring the whole health of an individual, not just at the point of care in the facility,” said Michael DeGeer, DPM, FACPS, FACFAS, vice president of population health management, Agnesian HealthCare. “Remote patient monitoring allows our clinicians to have access to patients’ health data, within the patient’s health record, while they are at home, which will provide the opportunity for clinicians to make informed interventions as needed.”

For more information: www.cerner.com, www.qualcommlife.com

Related Content

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Antithrombin Drug Ineffective in Heart Failure With Sinus Rhythm and Coronary Disease
News | Heart Failure | September 07, 2018
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction...
Tafamidis Improves Survival in Rare Heart Condition
News | Heart Failure | September 06, 2018
Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart condition called...
New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Overlay Init